STAAR Surgical (STAA): Broadwood Partners Urges Shareholders to Reject Alcon Merger Over Governance and Valuation Concerns
Summary
Broadwood Partners’ presentation argues that STAAR Surgical’s sale to Alcon is ill-timed, flawed, and undervalued. It claims STAAR’
Khrom Capital Pushes Acadia Healthcare (ACHC) Board to Pursue Sale, Slams Entrenched Leadership and Poor Capital Allocation
Summary
Khrom Capital, owning 5.5% of Acadia Healthcare, criticized the company’s decade-long underperformance, poor capital allocation, and entrenched
STAAR Surgical (STAA): Broadwood Capital Urges Shareholders to Reject Alcon Merger, Highlighting Governance Conflicts and Poor Timing
Summary
Broadwood Capital, owning 27.5% of STAAR Surgical, urged shareholders to vote against the proposed $28-per-share sale to Alcon,
Al Hartman Presses Silver Star Properties REIT (SLVS) Holders: Reject Current Board, Back Liquidation Plan Amid Alleged Misconduct and Value Destruction
Summary
Al Hartman’s Hartman Shareholder Alliance urges Silver Star investors to vote the BLUE proxy as a “last chance”
Broadwood Partners Challenges STAAR Surgical (STAA) Sale to Alcon, Citing Inopportune Timing, Governance Issues, and Undervaluation
Summary
Broadwood Partners, STAAR Surgical’s largest shareholder with a 27.5% stake, urged stockholders to vote against the proposed
Yunqi Capital Challenges STAAR Surgical (STAA)–Alcon Deal, Citing Undervaluation, Weak China Outlook Assumptions, and Governance Failures
Summary
Yunqi Capital, a 5.1% shareholder of STAAR Surgical, announced it will vote against the company’s proposed $28
Member discussion